Strategic fit Target institutions and partners seeking disease-modifying therapies for axonal degeneration, including MS, ALS, glaucoma, and peripheral neuropathies, leveraging Disarm's SARM1 inhibitor platform to position co-development or licensing discussions with neurodegenerative disease programs.

Acquisition context Given the Lilly acquisition in 2020 for up to 1.36B, position discussions around collaboration or staged licensing by emphasizing near-term value through preclinical-to-clinical milestones and risk-sharing in neurology indications.

Funding leverage With modest revenue and recent funding of 30M, target biotech banks, venture partners, and grant programs for co-funding late-stage development or expansion of the SARM1 inhibitor portfolio to accelerate IND-enabling studies.

Technical alignment Leverage Disarm’s tech stack and preclinical focus to engage CROs and contract manufacturers experienced in neurodegenerative therapy development, facilitating scalable manufacturing, GLP/GMP services, and analytical method development for regulatory readiness.

Market positioning Highlight competitive differentiation in a high-need CNS market by stressing a disease-modifying mechanism that aims to preserve axons; explore partnerships with specialty neurology clinics, patient advocacy groups, and diagnostic platforms to create ecosystem-driven adoption paths.